What’s the latest on Navicular Syndrome?

As an equine practitioner, you know that navicular syndrome (NS) can be a very challenging disease in your athlete patients. It is the most common cause of chronic forelimb lameness in performance horses. It is characterized by a gait change or lameness, and pain in the palmar area just where the navicular bone sits. Importantly, it is the result of mechanical forces and influenced by many factors including the horse’s conformation and the stresses from performance and use.

NS happens when the natural bone remodeling system is disrupted, and more bone is destroyed (osteolysis) than is produced, creating actual lesions on the navicular bone. While it is important to try and control the biomechanical aspects of NS, slowing the rate of bone turnover and alleviating the pain induced by abnormal bone osteolysis is key.

Tildren^® (tiludronate disodium) works to restore balance to the process of bone remodeling by slowing down the rate of osteolysis and therefore decreasing mineral loss.

To learn more about the bone remodeling process and how Tildren^® (tiludronate disodium) works,
click here for a short video.

Tildren^®(tiludronate disodium) is the only bisphosphonate that has been on the market for over 13 years and has sold more than 250,000 doses worldwide.

Backed by over a dozen published clinical studies supporting the safety and efficacy of tiludronate, Tildren^® (tiludronate disodium) has an unmatched track record when it comes to
treating navicular syndrome and providing lasting relief from osteolytic pain.